Systematic review of agents for the management of gastrointestinal mucositis in cancer patients
Purpose The aim of this study was to review the available literature and define clinical
practice guidelines for the use of agents for the prevention and treatment of gastrointestinal …
practice guidelines for the use of agents for the prevention and treatment of gastrointestinal …
Radiation-induced esophagitis in lung cancer
S Baker, A Fairchild - Lung Cancer: Targets and Therapy, 2016 - Taylor & Francis
Radiation-induced esophagitis is the most common local acute toxicity of radiotherapy (RT)
delivered for the curative or palliative intent treatment of lung cancer. Although concurrent …
delivered for the curative or palliative intent treatment of lung cancer. Although concurrent …
Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer
SC Chang, YC Lai, JC Hung, CY Chang - Medicine, 2019 - journals.lww.com
Background: Complications related to concurrent chemoradiotherapy (CCRT) such as acute
radiation-induced esophagitis (ARIE) may cause significant morbidity and unplanned …
radiation-induced esophagitis (ARIE) may cause significant morbidity and unplanned …
Prevention of acute radiation-induced esophagitis with glutamine in non-small cell lung cancer patients treated with radiotherapy: evaluation of clinical and dosimetric …
E Topkan, MN Yavuz, C Onal, AA Yavuz - Lung cancer, 2009 - Elsevier
BACKGROUND: The purpose of this study was to evaluate the efficacy of oral glutamine in
the prevention of acute radiation-induced esophagitis (ARIE) and weight loss in lung …
the prevention of acute radiation-induced esophagitis (ARIE) and weight loss in lung …
Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines
Purpose The aim of this study was to update the clinical practice guidelines for the use of
agents for the prevention and/or treatment of gastrointestinal mucositis (GIM). Methods A …
agents for the prevention and/or treatment of gastrointestinal mucositis (GIM). Methods A …
Risk factors of radiation-induced acute esophagitis in non-small cell lung cancer patients treated with concomitant chemoradiotherapy
ZC Zhang, J Xu, T Zhou, Y Yi, HS Li, HF Sun… - Radiation …, 2014 - Springer
Background To analyze the clinical and dosimetric risk factors of acute esophagitis (AE) in
non-small-cell lung cancer (NSCLC) patients treated with concomitant chemoradiotherapy …
non-small-cell lung cancer (NSCLC) patients treated with concomitant chemoradiotherapy …
Influence of oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung …
E Topkan, C Parlak, S Topuk, B Pehlivan - BMC cancer, 2012 - Springer
Abstract Background Glutamine (Gln) supplementation during concurrent
chemoradiotherapy (C-CRT) effectively reduces the incidence and severity of acute …
chemoradiotherapy (C-CRT) effectively reduces the incidence and severity of acute …
Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy
N Rodríguez, M Algara, P Foro, M Lacruz… - International Journal of …, 2009 - Elsevier
PURPOSE: To evaluate the risk factors for acute esophagitis (AET) in lung cancer patients
treated with concurrent 3D-CRT and chemotherapy. METHODS AND MATERIALS: Data …
treated with concurrent 3D-CRT and chemotherapy. METHODS AND MATERIALS: Data …
Effects of oral glutamine during abdominal radiotherapy on chronic radiation enteritis: a randomized controlled trial
A Vidal-Casariego, A Calleja-Fernández… - Nutrition, 2015 - Elsevier
Objective Glutamine has been proposed as a preventive treatment for toxicity related to
cancer therapies. The aim of this study was to test the efficacy of glutamine in the prevention …
cancer therapies. The aim of this study was to test the efficacy of glutamine in the prevention …
Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol
J Gong, A Osipov, J Lorber, M Tighiouart, AK Kwan… - Biomedicines, 2023 - mdpi.com
Advanced pancreatic cancer is underscored by progressive therapeutic resistance and a
dismal 5-year survival rate of 3%. Preclinical data demonstrated glutamine supplementation …
dismal 5-year survival rate of 3%. Preclinical data demonstrated glutamine supplementation …